Short answer
Boston Scientific (BSX) filed its Q3 2025 10-Q quarterly report on Nov 3, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $5.1B (up 20.3% year over year) with net income of $755M.
Q3 2025 key financials · XBRL
- Revenue
- $5.1B
- +20.3% YoY · +0.1% QoQ
- Net income
- $755M
- +61.0% YoY · −5.3% QoQ
- Operating margin
- 20.7%
- Gross margin
- 69.9%
- EPS (diluted)
- $0.51
- +59.4% YoY · −3.8% QoQ
Source: XBRL data from the Boston Scientific (BSX) Q3 2025 10-Q on SEC EDGAR. USD.
Boston Scientific Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Restructuring charges related to severance, facility closures, product line transfers including ACURATE neo2 and ACURATE Prime discontinuation
- Restructuring costs excluded from management's operating performance and segment profit assessments
- Non-GAAP measures used to assess core operational trends removing restructuring and currency impacts, no specific margin data given
- Forward-looking statements highlight risks and uncertainties, no updated guidance or near-term outlook included
Risk Factors
- No new or updated risk factors disclosed; risk section unchanged from most recent 10-K
- Legal/compliance risk: multiple directors and officers initiated Rule 10b5-1 trading plans for stock sales through 2026-2027
- Operational risk: reliance on executive stock sales under scheduled trading plans may impact insider ownership levels near term
- Financial risk: no specific liquidity, debt maturity, or currency risk updates in this filing segment
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Boston Scientific quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.